News & Updates
New Research shows promising, sustained results for personalized treatment of treatment-resistant depression Excerpt from the Press Release: BURLINGAME, Calif.–(BUSINESS WIRE)–Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced promising new clinical data on SAINT® therapy at the 2024 NYC Neuromodulation Conference, Aug 1-3. The research will be presented…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements…
Read More
Agency feedback from Type C meeting process supports the company’s proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 Excerpt from the Press Release: PHILADELPHIA, July 16, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ:…
Read More
Excerpt from the Press Release: PALO ALTO, Calf., July 16, 2024 /PRNewswire/ — Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced positive results of its first-in-human proof-of-concept study with EVO756. By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to…
Read More
– 300 patients enrolled in the study, including patients with and without the cognitive biomarker – – On track to report topline data in October 2024 – – Alto to host investor day focused on ALTO-100 on September 9, 2024 – Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)– Alto Neuroscience, Inc. (“Alto”) (NYSE:…
Read More Excerpt from the Press Release: SAN DIEGO, July 17, 2024 /PRNewswire/ — Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory diseases, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating BTX-9341, an investigational…
Read More ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial collaboration and supply agreements with Bayerand Johnson & Johnson Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Calif., July 16, 2024 (GLOBE NEWSWIRE) —…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif., July 17, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 24-week landmark data from the Population Extension cohort…
Read More
Excerpt from the Press Release: – 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks – Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control – Safety: 100% of 6E10 difluprednate-alone patients had no…
Read More
Alignment with FDA on Phase 3 study primary endpoint of Bayley-4 cognition and key secondary endpoint of Multi-Domain Responder Index (MDRI) Phase 3 study on track to initiate by the end of this year Excerpt from the Press Release: NOVATO, Calif., July 17, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?